Hong Kong Baptist University Researchers Achieve Preclinical Breakthrough for Osteogenesis Imperfecta Treatment & Receive FDA Orphan Drug Designation

Hong Kong Baptist University Researchers Achieve Preclinical Breakthrough for Osteogenesis Imperfecta Treatment & Receive FDA Orphan Drug Designation

Researchers from the School of Chinese Medicine at Hong Kong Baptist University (HKBU) have successfully developed a novel aptamer for the treatment of osteogenesis imperfecta (OI) with the aid of artificial intelligence technology. This represents the first time that...

Pin It on Pinterest